Redhill Biopharma - ADR

NASDAQ:RDHL   3:56:40 PM EDT
8.85
0.00 (0.00%)
Earnings Announcements

RedHill Biopharma Reports Q3 Revenue $21 Million

Published: 11/12/2020 12:18 GMT
Redhill Biopharma Ltd (RDHL) - Q3 Revenue $21 Million.
Redhill Biopharma - Opaganib's Covid-19 Global Phase 2/3 Study Advancing With Nearly 50% of Patients Enrolled & U.S. Phase 2 Study Over 90% Enrolled.
Revenue is expected to be $28.02 Million
Adjusted EPS is expected to be -$0.26

Next Quarter Revenue Guidance is expected to be $37 Million
Next Quarter EPS Guidance is expected to be -$0.01

More details on our Analysts Page.